Immune checkpoint blockade

The hope for immunotherapy as a treatment of lung cancer?

Research output: Contribution to journalArticle

Abstract

Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.

Original languageEnglish (US)
Pages (from-to)126-132
Number of pages7
JournalSeminars in Oncology
Volume41
Issue number1
DOIs
StatePublished - Feb 2014

Fingerprint

Immunotherapy
Lung Neoplasms
Survival
Immunoglobulin Isotypes
Vaccines
Clinical Trials
Antibodies
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Immune checkpoint blockade : The hope for immunotherapy as a treatment of lung cancer? / Brahmer, Julie.

In: Seminars in Oncology, Vol. 41, No. 1, 02.2014, p. 126-132.

Research output: Contribution to journalArticle

@article{51974e03a1924e14bf1e96a07e2ffe64,
title = "Immune checkpoint blockade: The hope for immunotherapy as a treatment of lung cancer?",
abstract = "Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.",
author = "Julie Brahmer",
year = "2014",
month = "2",
doi = "10.1053/j.seminoncol.2013.12.014",
language = "English (US)",
volume = "41",
pages = "126--132",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immune checkpoint blockade

T2 - The hope for immunotherapy as a treatment of lung cancer?

AU - Brahmer, Julie

PY - 2014/2

Y1 - 2014/2

N2 - Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.

AB - Over the past 20 years, immunotherapy has not played a role in the treatment of lung cancer outside of clinical trials. Early trials with vaccines yielded promising results, but phase III trials have yet to show an improvement in survival. Recently, immune checkpoint pathway inhibitors have yielded exciting and consistent activity across this class of antibodies. However, phase III trials are now ongoing. Currently, the hope of bringing immunotherapy to lung cancer patients lies in this class of drugs. Only time will show us if these antibodies will yield an improvement in long-term survival. This review will focus on checkpoint pathway inhibitors that have completed early-phase trials.

UR - http://www.scopus.com/inward/record.url?scp=84894499071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894499071&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.12.014

DO - 10.1053/j.seminoncol.2013.12.014

M3 - Article

VL - 41

SP - 126

EP - 132

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1

ER -